tag:blogger.com,1999:blog-5006185839221031362.post7088644543956869651..comments2023-09-15T16:54:53.401+02:00Comments on HEALTH ECONOMICS BLOG - Trends, Politics, Opinions etc. in biotech & pharma industry: Prices negotiated in Germany most likely are not going to be confidential after allUnknownnoreply@blogger.comBlogger3125tag:blogger.com,1999:blog-5006185839221031362.post-49948694204153496442012-08-23T22:09:11.189+02:002012-08-23T22:09:11.189+02:00thanks JF I agree its not easy ;)thanks JF I agree its not easy ;)ustaginnus@hotmail.comhttps://www.blogger.com/profile/13405997204504599670noreply@blogger.comtag:blogger.com,1999:blog-5006185839221031362.post-22511208914563102952012-07-17T11:09:02.821+02:002012-07-17T11:09:02.821+02:00Hi Ulf, I'm interested in your presentation bu...Hi Ulf, I'm interested in your presentation but access was denied. Could you please send a copy to me @ geoffrey.wilson@ge.com<br />Many thanks, GeoffGeoff Wilsonnoreply@blogger.comtag:blogger.com,1999:blog-5006185839221031362.post-3026673289368075392012-07-14T10:58:45.357+02:002012-07-14T10:58:45.357+02:00Great presentation!
Thanks Ulf.
Unless you are sur...Great presentation!<br />Thanks Ulf.<br />Unless you are sure to get a clearly positive assessment, the high price strategy seemes to be a mid-term losing one. Delaying launch in Germany is no better... short-term & long-term.<br />For good (not great) products, right pricing from strat may be the preferred approach.<br />But what is right pricing?<br />Cheers,<br />JF at PharmExpandJF Grenierhttp://pharmexpand.comnoreply@blogger.com